Scientists have demonstrated that ASP-400 a specific inhibitor of the protease plasma kallikrein may provide a new therapeutic approach for the treatment of diabetic retinopathy.
Researchers from Joslin Diabetic Centre, Boston, and ActiveSite Pharmaceuticals, Inc.,SanFrancisco, jointly conducted this study. The study was partly funded by the Juvenile Diabetic Research Foundation(JDRF), and published in the February 2009 issue of the journal Hypertension.
continuous systemic administration of ASP-440 proved effective in decreasing hypertension-induced increased retinal vascular permeability in rodents, by as much as 70%.
Increased retinal vascular permeability is a characteristic finding in diabetic retinopathy and a primary cause of diabetic macular edema, a leading cause of visual impairment associated with diabetes.
Hypertension is a known risk factor for the development of retinopathy. ASP-440 was also found to be effective in lowering the elevated blood pressure in these animals.
According to experts previous JDRF-funded research by same researchers, able to pointed out plasma kallikrein as a potential therapeutic target for diabetic retinopathy. Current study added further steps by suggesting opportunities to inhibit plasma kallikerein and retinal blood vessel lekage.
However, experts are looking forward to open up locked doors to find out the therapeutic potential of FASO-440 related to different diabetic complications that links diabetic retinopathy.
Filed under Diabetic Retinopathy, Eye Treatment | Tags: ActiveSite Pharmaceuticals, ASP-440, diabetic macular edema, Diabetic Retinopathy, Inc, Joslin Diabetic Centre, Protease Inhibitor, protease plasma kallikrein, vessel lekage | Comment Below